Skip to content
Stack & save: 10% off 3+ vials, 15% off 5+ · Free shipping over $250
Cart 0
Compound Files

ARA-290 Research Guide: Cibinetide and the Repair-Signaling Question

ARA-290 grew from a question about separating erythropoietin’s biological activities. Read its design history, small-fiber studies, and the limits of a promising mechanism.

Hero Peptides Research TeamUpdated Nov 20265 min read

Quick facts

Literature names ARA-290; cibinetide
Molecule class Synthetic 11-residue peptide
Design background Modeled on the exposed helix-B surface of erythropoietin
Hero catalog size 10 mg
Research distinction Study formulation and catalog material require separate documentation
Hero product Ara-290

ARA-290 is a synthetic peptide studied under the name cibinetide. Its research story begins with an intriguing design question: could a short peptide reproduce selected tissue-protective signals associated with erythropoietin without reproducing its red-blood-cell effects?

Hero’s supplied export lists Ara-290 in a 10 mg format. The useful background includes the peptide’s structural inspiration, the human small-fiber studies, and the distinction between an experimental signal and a broadly demonstrated clinical benefit.

Origin story: an erythropoietin-inspired peptide

Brines and colleagues reported tissue-protective peptides designed from erythropoietin’s three-dimensional structure in 2008. Instead of copying the full protein, they investigated a shorter design based on residues exposed at the surface of helix B. That work provides the structural background to the ARA-290 research program (Brines et al., 2008).

ARA-290 is generally described in the clinical literature as an 11-residue peptide. Cibinetide is a useful additional search term. Historical helix-B designs and later preparations should still be checked for exact sequence and terminal chemistry rather than treated as interchangeable by nickname.

For a laboratory, that distinction is practical. A paper’s test article has a defined specification; a supplier’s sample needs its own identity documentation. A related name is a starting point for comparison, not proof that two materials match.

How ARA-290 research approaches repair signaling

The development program investigated nonerythropoietic signaling associated with tissue protection. The literature often describes an innate repair receptor pathway. That terminology reflects a mechanistic research framework; it is not evidence that a peptide repairs every damaged tissue in every setting (Brines et al., 2008).

Mechanistic work becomes more informative when the experiment identifies its model, receptor context, and measured response. A change in an injury marker, for example, is different from a direct measurement of nerve-fiber structure. Each endpoint can contribute, but they answer different questions.

This is also why ARA-290 should not be reduced to a generic “nerve peptide” label. A good study asks a narrower question and chooses controls that can distinguish the proposed pathway from unrelated effects. The interesting part is whether the evidence connects those steps.

What the small-fiber studies found

Heij and colleagues studied ARA-290 in a randomized, double-blind exploratory trial involving 22 people with sarcoidosis and symptoms of small-fiber neuropathy. A neuropathy symptom score improved more in the active group. Some other measurements, including the reported pain-intensity measure, improved similarly in both groups (Heij et al., 2012).

That mixed pattern matters. Selecting only the favorable endpoint would give an incomplete picture of what the pilot actually found.

Study Setting Question addressed Important limit
Brines et al., 2008 Peptide design and preclinical experiments Can a short EPO-inspired design retain selected tissue-protective activity? Preclinical findings do not establish broad human efficacy
Heij et al., 2012 Small randomized sarcoidosis pilot Do neuropathy-related measurements change? Small sample and differing results across endpoints
Culver et al., 2017 Sarcoidosis-associated small-fiber loss Can corneal and skin nerve-fiber measurements detect a response? Structural findings remain specific to the studied population and design

Culver and colleagues subsequently reported changes in small nerve-fiber abundance in a controlled cibinetide study. The work used corneal measurements and skin-related assessments to examine the biological question from a different angle (Culver et al., 2017).

Where interpretation needs restraint

A study of sarcoidosis-associated small-fiber loss cannot automatically establish effects in diabetic neuropathy, traumatic injury, or an otherwise healthy population. Those settings differ in underlying biology and require their own evidence. Nor does a short study settle long-term outcomes.

Structural and symptom measurements should be kept separate when interpreting a result. An imaging change may support a biological hypothesis without demonstrating the full patient benefit someone hopes to infer. Conversely, a symptom score alone does not identify the cellular mechanism behind it.

Read the primary endpoint before the conclusion, then inspect the comparator and the other outcomes. If a summary says only that a study was “positive,” ask what was positive and how the question was defined. That approach is more useful than treating an entire field as either proven or disproven.

Laboratory notes for a 10 mg catalog format

The supplied 10 mg listing identifies a catalog quantity. It does not establish the peptide’s terminal form, net peptide content, solution concentration, or equivalence to clinical-development material. Those details belong in matching product and lot documentation.

Before adapting a published assay, compare sequence, modification, preparation method, and analytical identity. Keep controls appropriate to the chosen biological system. For cell-based work, unwanted components or incompatible preparation conditions can obscure the very response the experiment is trying to measure.

Use documented storage and stability conditions rather than assigning a universal shelf life to the peptide. Record lot, preparation date, solvent, and relevant handling history. Researchers comparing neuropeptide topics may also find the separate VIP research guide useful, while keeping its receptor biology distinct.

ARA-290 research FAQ

Is ARA-290 the same literature name as cibinetide?

Cibinetide is a name used for ARA-290 in the clinical-development literature. Exact material specifications still need to be matched when comparing a sample with a paper.

Is ARA-290 simply erythropoietin?

No. It is a shorter synthetic peptide developed from a structural feature of erythropoietin. The full protein and the peptide are distinct test articles.

Do the small-fiber studies establish a universal nerve treatment?

No. The cited studies address specific populations and endpoints. Extending those findings to other conditions or preparations requires additional evidence.

What ARA-290 size does Hero list?

The supplied catalog lists 10 mg. Consult the current product and lot documentation for the identity and specifications required by a laboratory method.

Ara-290. View catalog product

References

  1. Brines M, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA 2008. Source.
  2. Heij L, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med. 2012. Source.
  3. Culver DA, et al. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Invest Ophthalmol Vis Sci. 2017. Source.
For laboratory research use only. Not for human or veterinary use. This article is educational and is not medical advice.

Read next

Add 3 vials for 10% off
Build my stack